Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28030485 | 0.91 | NPC1 (0.39) | NPC1PDE5AKCNA5ALOX5KMT2A | |
| SCHEMBL14800179 | 0.85 | NPC1 (0.42) | NPC1PDE5AKMT2AMAPTHDAC1 | |
| SCHEMBL637196 | 0.84 | NPC1 (0.42) | NPC1PDE5AKMT2AMAPTDGAT1 | |
| SCHEMBL14800966 | 0.80 | NPC1 (0.40) | NPC1KMT2AMAPT | |
| SCHEMBL30645867 | 0.79 | NPC1 (0.40) | NPC1PDE5AMAPTHDAC1HDAC8 | |
| SCHEMBL32686737 | 0.78 | NPC1 (0.40) | NPC1KMT2ALMNA | |
| SCHEMBL9124674 | 0.76 | ALOX5 (0.42) | PDE5AKCNA5ALOX5KMT2AMAPT | |
| SCHEMBL14816254 | 0.75 | PLA2G4A (0.41) | NPC1ALOX5KMT2AMAPTHDAC1 | |
| SCHEMBL14816252 | 0.75 | PLA2G4A (0.41) | NPC1ALOX5KMT2AMAPTHDAC1 | |
| SCHEMBL30470561 | 0.75 | NPC1 (0.39) | NPC1MAPTDGAT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9556175-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160194327-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-07 | — | — | US | disclosed |
| US-9321791-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20150291627-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-15 | — | — | US | disclosed |
| EP-1532149-B9 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2308878-A2 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-1532149-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2070539-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2060573-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058311-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2121/4885PDE5A 109/4885KCNA5 2318/4885 |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2121/4885PDE5A 109/4885KCNA5 2318/4885 |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20150291627-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20160194327-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | NPC1 1409/4885PDE5A 168/4885KCNA5 2213/4885 |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | NPC1 2177/4885PDE5A 99/4885KCNA5 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.